However, Accili (39) argued that diabetic ketoacidosis after COVID-19 should require conventional insulin therapy if the virus causes permanent loss of β-cell function, but the challenge in clinical practice is mainly extrinsic to the β-cells. The gene discussed is INS; the disease is diabetic ketoacidosis.